Literature DB >> 21314842

Adenovirus-mediated overexpression of cardiac troponin I-interacting kinase promotes cardiomyocyte hypertrophy.

Lin Wang1, Hui Wang, Jue Ye, Rui-Xia Xu, Li Song, Na Shi, Yan-Wan Zhang, Xi Chen, Xian-Min Meng.   

Abstract

1. Cardiac troponin I-interacting kinase (TNNI3K) is a novel cardiac-specific kinase gene. Quantitative real-time reverse transcription polymerase chain reaction analysis showed a significant increase in TNNI3K mRNA expression in hypertrophic cardiomyocytes induced by endothelin-1 (ET-1). The aim of the present study was to investigate the effects of TNNI3K on neonate rat cardiomyocyte hypertrophy induced by ET-1. 2. Adenoviruses were amplified in 293A cells. To determine a reasonable adenovirus infection dose cardiomyocytes were infected with an adenovirus carrying human TNNI3K (Ad-TNNI3K) at varying multiplicity of infection (MOI) and the expression of TNNI3K was analysed by western blot. 3. Cardiomyocytes were infected with either a control adenovirus carrying green fluorescent protein (Ad-GFP) or Ad-TNNI3K. Compared with Ad-GFP, the Ad-TNNI3K induced an increase in sarcomere organization, cell surface area, (3) H-leucine incorporation and β-MHC re-expression. This type of hypertrophic phenomenon is similar to that observed in Ad-GFP-infected hypertrophic cardiomyocytes induced by ET-1. To determine the functional role of TNNI3K in ET-1-induced hypertrophic cardiomyocytes, the cells were infected with Ad-GFP or Ad-TNNI3K. Ad-TNNI3K induced an increase in sarcomere organization, cell surface area and (3) H-leucine incorporation compared with Ad-GFP. 4. These results suggest that TNNI3K overexpression induces cardiomyocytes hypertrophy and accelerates hypertrophy in hypertrophic cardiomyocytes. Therefore, TNNI3K might be an interesting target for the clinical treatment of hypertrophy.
© 2011 The Authors. Clinical and Experimental Pharmacology and Physiology © 2011 Blackwell Publishing Asia Pty Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21314842     DOI: 10.1111/j.1440-1681.2011.05499.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  10 in total

Review 1.  Troponin I-interacting protein kinase: a novel cardiac-specific kinase, emerging as a molecular target for the treatment of cardiac disease.

Authors:  Hind Lal; Firdos Ahmad; Shan Parikh; Thomas Force
Journal:  Circ J       Date:  2014-06-05       Impact factor: 2.993

2.  Overexpression of TNNI3K, a cardiac-specific MAPKKK, promotes cardiac dysfunction.

Authors:  Hao Tang; Kunhong Xiao; Lan Mao; Howard A Rockman; Douglas A Marchuk
Journal:  J Mol Cell Cardiol       Date:  2012-10-16       Impact factor: 5.000

3.  Inhibition of the cardiomyocyte-specific kinase TNNI3K limits oxidative stress, injury, and adverse remodeling in the ischemic heart.

Authors:  Ronald J Vagnozzi; Gregory J Gatto; Lara S Kallander; Nicholas E Hoffman; Karthik Mallilankaraman; Victoria L T Ballard; Brian G Lawhorn; Patrick Stoy; Joanne Philp; Alan P Graves; Yoshiro Naito; John J Lepore; Erhe Gao; Muniswamy Madesh; Thomas Force
Journal:  Sci Transl Med       Date:  2013-10-16       Impact factor: 17.956

4.  Glucagon-like peptide 1 improves insulin resistance in vitro through anti-inflammation of macrophages.

Authors:  C Guo; T Huang; A Chen; X Chen; L Wang; F Shen; X Gu
Journal:  Braz J Med Biol Res       Date:  2016-11-21       Impact factor: 2.590

5.  New Insights into 4-Anilinoquinazolines as Inhibitors of Cardiac Troponin I-Interacting Kinase (TNNi3K).

Authors:  Christopher R M Asquith; Tuomo Laitinen; Carrow I Wells; Graham J Tizzard; William J Zuercher
Journal:  Molecules       Date:  2020-04-07       Impact factor: 4.411

Review 6.  MiR-223-3p in Cardiovascular Diseases: A Biomarker and Potential Therapeutic Target.

Authors:  Meng-Wan Zhang; Yun-Jie Shen; Jing Shi; Jian-Guang Yu
Journal:  Front Cardiovasc Med       Date:  2021-01-20

Review 7.  The Diverse Roles of TNNI3K in Cardiac Disease and Potential for Treatment.

Authors:  Caroline Pham; Noelia Muñoz-Martín; Elisabeth M Lodder
Journal:  Int J Mol Sci       Date:  2021-06-15       Impact factor: 5.923

8.  TNNI3K, a cardiac-specific kinase, promotes physiological cardiac hypertrophy in transgenic mice.

Authors:  Xiaojian Wang; Jizheng Wang; Ming Su; Changxin Wang; Jingzhou Chen; Hu Wang; Lei Song; Yubao Zou; Lianfeng Zhang; Youyi Zhang; Rutai Hui
Journal:  PLoS One       Date:  2013-03-05       Impact factor: 3.240

9.  TNNI3K is a novel mediator of myofilament function and phosphorylates cardiac troponin I.

Authors:  Hui Wang; Lin Wang; Li Song; Yan-Wan Zhang; Jue Ye; Rui-Xia Xu; Na Shi; Xian-Min Meng
Journal:  Braz J Med Biol Res       Date:  2013-02-01       Impact factor: 2.590

10.  Treatment with 20(S)-ginsenoside Rg3 reverses multidrug resistance in A549/DDP xenograft tumors.

Authors:  Chao Liu; Quan Gong; Ting Chen; Juan Lv; Zhiping Feng; Pengjie Liu; Zhiyong Deng
Journal:  Oncol Lett       Date:  2018-01-24       Impact factor: 2.967

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.